TEST:

Quest Flow Cytometry MRD for Myeloma

Myeloma Measurable Residual Disease (MRD) Detection, Flow Cytometry - Next-generation flow cytometry (NGFC) is an ultra-sensitive tool for detecting measurable residual disease (MRD) in hematologic malignancies. MRD refers to the presence of cancer cells in a patient's bone marrow or peripheral blood during or after treatment, which is not detectable by conventional diagnostics methods. MRD tests provide crucial prognostic information to clinicians, helping them evaluate treatment response and determine if a patient is in stable remission or relapse.